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SUPPLEMENTAL METHODS

Study subjects
The Icelandic Sleep Apnea Cohort (ISAC) was assembled from patients diagnosed with moderate to severe OSA [apnea hypopnea index (AHI) good quality abdominal magnetic resonance imaging (MRI) at baseline, . PAP users were required to have and with available smartcard download for assessment of objective PAP usageadherence information at the 2 year follow-up. Based on these criteria, aA total of 228 subjects with at least some PAP usage were available for analysis. Of these, 7 (3%) participants were missing blood samples at baseline or follow-up, resulting in our a final sample of 221 PAP users (177 full, 44 partial) for analysis. For non-PAP users, good quality sleep studies and abdominal MRIs at baseline were again required. PAP non-usersTo assure these subjects accurately represented the untreated OSA population, were also required that theyto have returned their PAP device within 1 year of starting therapy and did not have throat surgery between baseline and 2-year follow-up; a subset (n=16) patients had a prescribed mandibular advancement device.. Given these criteria, a A total of 89 non PAP users were available for analysis, 1 (1%) of which was missing blood at baseline, resulting in our final sample of 88 nonusers for analysis.
ProceduresBaseline Evaluation
At baseline, subjects received a physical examination, completed standardized questionnaires, overnight polysomnography, abdominal MRI, and blood was drawn in the morning after sleep from the antecubical vein of fasting untreated subjects. was calculated as weight in kilograms divided by the square of height in meters. Blood pressure was measured twice by manual sphygmomanometer after a 10 minute resting period, separated by a 2 minute interval, and averaged for analysis.
Sleep Study and OSA Severity Measures
Polysomnography (PSG):
Subjects had a sleep study while untreated with an Embletta type 3 portable monitor or Embla 12 channel system that records the same channels (Embla; Flaga Inc., Reykjavik, Iceland). Sleep study recordings were scored in a uniform manner at the Sleep Study Reading Unit of the University of Pennsylvania. An apnea-hypopnea index (AHI) and oxygen desaturation index (ODI) were measured. The apnea-hypopnea index (AHI) was defined as the average number of apneas An apnea was defined as (a ≥80% drop in airflow for ≥10 seconds), and a hypopneas as 
Magnetic Resonance Imaging (MRI) of Abdomen:
All patients underwent MRI of the entire abdomen. Axial, coronal and sagittal images were acquired using a 1.5 Tesla scanner with a body coil (Siemens Avanto, Germany). The adipose areas from each slice were summed in order to assess the visceral, subcutaneous and total (visceral + subcutaneous) abdominal fat volumes and visceral fat volume. Assessment of reliability by comparing results obtained on 2 occasions by 2 different observers showed negligible variance due to analysis procedures, as described (for further details, seein previous publications (2, 4) ).
Blood Sampling
Blood Sampling:
Blood was drawn in the morning after sleep from the antecubital vein of fasting untreated participants at baseline and again two-years after treatment initiation. Specimens were collected in SST vacutainers (Greiner, Kremsmunster, Austria) and allowed to clot at room temperature for 20 minutes prior to centrifugation for 10 minutes at 3,000 rpm. The serum samples were subsequently stored at -20°C after separation. Enzyme-linked immunosorbent assay was used in order to determine the serum levels of ICAM-1 and VCAM-1 (R&D Systems, Minneapolis, MN). The assay was performed according to directions of the manufacturer. We ensured quality control in the samples by inserting internal controls (running high and low concentration quality controls) with known values to monitor the variability of the assays. user, non-user) were performed using ANOVA and Chi-square or Fisher's exact tests. Our primary outcome measures were the changes in ICAM-1 and VCAM-1, calculated as within subject follow-up levels minus baseline levels.
Follow Up Evalulation and PAP Adherence
Linear Correlation Analyses:
We initially examined whether there was a significant lLinear correlations between ICAM-1 and VCAM-1 levels and between baseline levels and change scores usingwere evaluated using
Pearson correlation coefficients (r). A strong correlation between baseline and change level was observed, and therefore we adjusted for baseline levels in all of our statistical analyses of change scores. To determine which measures of obesity best captured the variability in ICAM-1 and VCAM-1 levels, we assessed the Pearson correlations between clinical (BMI, waist, neck and hip circumference, and waist-to-hip ratio) and MRI (total, subcutaneous, and visceral abdominal fat volume) measures of obesity and baseline ICAM-1 and VCAM-1 levels. Statistical tests and comparing the strength of the correlations between obesity measures and baseline levels were obtained using a nonparametric bootstrap re-sampling procedure (1,000 replications). Similarly, we examined whether there was anythe correlation between baseline OSA severity measures(Apnea Hypopnea Index, Oxygen Desaturation Index, SaO2 nadir, and percent time SaO2 < 90) and baseline ICAM-1 and VCAM-1 levels.
Association with PAP usage:
In our primary analyses, wWe assessed whether there was a significant association between change in cellular adhesion moleculetwo-year changes in CAM levels and PAP usage groups (full, partial, non) using an analysis of covariance (ANCOVA), comparing mean change among PAP usage groups). If significant differences were observed among PAP usage groups, we then examined the pairwise differences between full, partial, and non-users. Results are presented as predicted least square mean change (Δ) ± standard error (SE). As a complementary analysis,
given the ordinal nature of our PAP usage We also assessed whether there was evidence for a linear trend (or dose effect of PAP use) across the usage groups. This analysis was performed by including PAP usage group in our models as a continuous variable (1=full, 2=partial, 3=non), rather than a categorical variable. Finally, within the full and partial users only, we examined the relationship between continuously measured PAP use during the 28 nights prior to follow-up visit, which was measured as both the average number of hours used per day as well as the total number of nights used, using a linear regression (results presented as β-estimate ± SE).
We next exploreassessed whether the relationship between PAP and change in adhesion molecules was moderated by obesity severity as reflected in BMI defined strata (<30, 30-35 and ≥35 kg/m 2 ). This was assessed by firstby examining whether there was evidence for significant interaction between PAP usage and BMI stratagroup, as well as and subsequently by examining the associations within BMI strata. Interaction was assessed by including main effect terms (PAP use and BMI group) as well as an interaction term (PAP use x BMI group) in our models. If we observed evidence forSignificant interaction between PAP and BMI group, we were able to conclude that the observed suggests that the relationship between PAP usage and CAM changes in biomarker levels was likely is different acrosswithin BMI strata. Analyses within BMI strata were performed using identical methods to those described above for the overall population.
Complementary analyses replacing BMI strata with visceral abdominal fat tertiles were performed.
Exploratory Analysis:
As an exploratory analysis, w Within the full and partial users only, we examined the relationship between continuous PAP usage, measured as both the average hours/day and the total number of nights used over the last 28 days. Among non-users only, wee examined whether there was evidence of an association between baseline OSA severity measures (measured as apnea hypopnea index, oxygen desaturation index, SaO2 nadir, and percent time SaO2<90) and change in cellular adhesion molecule levels among the non-users only. Both analyses were conducted using linear regression Similar methods to those described above were used for assessing the relationship between baseline OSA severity and change in ICAM-1 or VCAM-1.
Due to the continuous nature of our OSA severity measures, we used a linear regression analysis and results are presented as β-estimate ± SE.
Assessment of Confounders:
In addition to the baseline biomarker levels, we considered as potential confounders any variable for which we had information that showed either significant differences among our PAP usage or BMI groups or that was previously mentioned in the literature as effecting cellular adhesion molecules. This listpotential confounders included age, gender, BMI, Epworth Sleepiness Score (ESS), hypertension, obstructive lung disease, smoking status, statin use, exercise, and baseline OSA severity. To control for both baseline levels and potential change in covariates, cContinuous confounders (e.g. BMI) were modeled included as baseline levels and change from baseline (when available) and dichotomous covariates (e.g. hypertension, statin use) were modeled using variables representing possible baseline and follow-up combinations (no, no; no, yes; yes, no; yes, yes). Inclusion of covariates to control for confounding was based on whether control for the covariate materially changed the estimated effect of PAP use on biomarker change. . That is, This was done by adding potential confounders were included in a forward stepwise fashion, retaining the variable that resulted in the largest percent change in coeffeicients at each step and stopping when inclusion of another variable resulted in a change in coefficient of <15%. This strategy was chosen to provide adequate control for confounding while reducing the number of variables required, an important consideration for strata with smaller sample sizes.
Based on these analyses, our final adjusted model for ICAM-1 change included covariates for baseline ICAM-1, BMI, BMI change, and hypertension status at baseline and follow-up. The model was similar for VCAM-1, but also included statin use at baseline and follow-up. The results of this process are presented in Tables E1A and E1B. Due to the high level of correlation among OSA severity measures and PAP usage group, wWe assessed the impact of adjustment for the four OSA severity measures separately and report this in the results.
Propensity Score Matching Sub-Sample Analysis:Propensity Score Subclassification
To better control for bias due to baseline covariate imbalance in our assessment of the effect of PAP treatment, Wwe used sub-classification based on propensity score (PS) quintiles based implemented a propensity score (PS) matching analysis based on on an established sequential heuristic and diagnostic conditions describeddescribed by Maislin and Rubin (7) and other previous publications (8) (9) (10) (11) (12) . Briefly, the heuristic consists of 3 steps that can be repeated as necessary to satisfy a set of "propensity score diagnostics" (described by Maislin & Rubin (7)).
First, a model including main effects for all desired covariates is fit to obtain PS quintiles.
Second, within quintile differences and other PS diagnostic information are analyzed to identify the most important cross-product and squared terms for inclusion in the PS model. Third, a PS model including all main effects and relevant cross-product and squared terms is estimated, and subjects in each treatment group with insufficient "covariate overlap" (as defined by the propensity scores) are excluded. Through the PS heuristic, a subset of PAP full and non-users are identified, such that there was within subclass balance with respect to measured covariates. This resulting covariate balance is similar to that expected through randomization, and thus selection bias is minimized and causal inferences can be made from the observed results.
Covariates included in the heuristic were: baseline ICAM-1, baseline VCAM-1, age, BMI, After the PS matched sample was created, aAnalyses comparing the change in ICAM-1 and VCAM-1 between full and non-users were within the PS designed comparison were conducted using a linear regression an ANCOVA model, as described above, with PAP usage group as a predictor. The models were adjusted for PS quintile, as well as and baseline ICAM-1 or VCAM-1. in order to further control for any potential residual differences after matching. The results from these analyses were then compared to those from the overall observational study.
Significance Level:
Primary tests for PAP use differences in changes in ICAM-1 and VCAM-1 were each evaluated with type 1 error set to α = 0.05. For each variable, if p<0.05 then a Tukey multiple comparisons correction was used for significance in our post hoc pairwise comparisons. Interaction tests were conducted using α = 0.10 to account for the generally low power of such tests in order to reduce the likelihood of missing an important interaction.
Post Hoc Power Calculation:
Based on our observed results, wWe estimate that PAP usage explains approximately 3.5% of the variability in ICAM-1 changes and 2.5% of the variability in VCAM-1 change. Given our sample size of 309 for analysis and our alpha level of 0.05, we have 95% and 82% power to find these effect sizes for ICAM-1 and VCAM-1, respectively. We note that dDue to the reduction in sample size, we have more limited power to find similar effects within our BMI strata, which have approximately 100 participants in each. Using this sample size, our estimated power is 52%
for ICAM-1 change and 37% power for VCAM-1 change. We would have 80% power to find an association in our BMI strata if PAP usage explains 6.4% of the variance, which reflects a small to moderate effect size based on Cohen's effect size definitions (13). Therefore, while our negative results in BMI strata should be interpreted with caution, we have adequate power to find clinically meaningful effect sizes in our analyses.
SUPPLEMENTAL RESULTS
Correlations between Obesity and CAM Levels
The results of analyses exploring the correlations between clinical and MRI measures of obesity and both ICAM-1 and VCAM-1 are presented in Table E12 ; . Results are presented as Pearson correlation coefficients and ICAM-1 and VCAM-1 were natural log transformed for normality. We observed significant associations between ICAM-1 and BMI (p=0.002), subcutaneous abdominal fat (p=0.002), total abdominal fat (p=0.004), and hip circumference (p=0.03). No association was seen between ICAM-1 and visceral fat volume and Nno associations were seen between obesity measures and VCAM-1 levels.
PAP usage and BMI Subgroup Specific Change in ICAM-1 and VCAM-1
The unadjusted mean ± standard deviation levels of ICAM-1 and VCAM-1 at baseline and followup are presented in Figure E2 E1 and Table E3E2 , stratified by PAP usage and BMI group. The pvalues presented test whether the change from baseline to follow-up was significantly different from zero. In these unadjusted analyses, we observed significant decreases in ICAM-1 for full users, overall (p=0.01) and when restricted to the most obese patients only (p=0.04). For VCAM-1, we observed significant increases in the overall population for all 3 PAP usage groups (p<0.01 for each), as well as for full (p=0.01) and non-users (p=0.02) with BMI≥35, partial users with BMI 30-35 (p=0.04), and non-users with BMI<30 (p=0.03).
Subgroup specific adjusted least square mean changes are presented in Table E4 . Similar to Table   E3 , the p-values in this table are testing whether the subgroup specific mean change is significantly different from zero, adjusted for baseline CAM level, BMI, change in BMI, hypertension and baseline and follow-up and statin use at baseline and follow-up (for VCAM-1 change only). We observed significant decreases in ICAM-1 for full users overall (p<0.001) and in both the BMI 30-35 (p=0.002) and BMI≥35 (p=0.04) strata, and for partial users with BMI<30 (p=0.03). We observed significant increases in ICAM-1 for non-users, both overall (p=0.02) and when restricted to the most obese (p<0.001). For VCAM-1, we observed significant increases for all 3 PAP usage groups in the overall population (p<0.05 for each comparison), for the most obese full users (p=0.009) and for non-users in each of the 3 BMI strata (p<0.006 in each strata).
Associations between continuous PAP use and Change in ICAM-1 and VCAM-1
Complementary analyses examining the relationship between both average hours of PAP use and total nights of PAP use over the last 28 nights and CAM change are presented in Table E35 .
Analyses were performed only in the subgroup of full and partial PAP users (n=221) and results are presented as β-estimates ± standard errors, adjusted for baseline CAM level, BMI, change in BMI, hypertension and baseline and follow-up and statin use at baseline and follow-up (for VCAM-1 change only). We found significant associations within the BMI≥35 group between ICAM-1 change and both average hours (p=0.02) and total nights (p=0.04) used; for each outcome, more use resulted in larger decreases in ICAM-1.
Impact of OSA Severity Adjustment on Association between PAP usage and CAM Change
Results from analyses exploring the impact of adjustment for baseline OSA severity on our primary analyses are presented in Table E6 . OSA severity was measured using 4 different metrics: 1) Apnea Hypopnea Index (AHI), 2) Oxygen Desaturation Index (number of desaturation events >4% per hour), 3) minimum SaO2 reached during the night (SaO2 nadir) and 4) percent of night time with Table   3 ) separately to assess any impact on the significance, magnitude or interpretation of results.
SaO2<90. Each variable was added to the fully adjusted model (presented in the manuscript
Overall, adjustment for OSA severity had no significant impact on the observed ICAM-1 result. For VCAM-1, results remained significant when adjusted for SaO2 nadir and percent time SaO2<90, but became non-significant after adjustment for AHI (p=0.18) and ODI (p=0.06). However, the overall relationship between the PAP groups remains similar, as evidenced by suggestive linear trends (p<0.08) in all analyses.
Association between baseline OSA Severity and CAM Change
The associations between baseline measures of OSA severity and the magnitude of change in ICAM-1 and VCAM-1 among PAP non-users are presented in Table E73 . Analyses are restricted to non PAP users (n=88) and results are presented as β-estimates ± standard errors, adjusted for baseline CAM level, BMI, change in BMI, hypertension and baseline and follow-up and statin use at baseline and follow-up (for VCAM-1 change only). We observe significant associations between ODI (p=0.02), SaO2 nadir (p=0.02) and percent time SaO2<90 (p=0.03) and ICAM-1 change in the most obese patients. In each case, more severe OSA led to larger increases in ICAM-1. We also found significant associations with AHI in the BMI 30-35 strata (p=0.03) and for SaO2 nadir in the overall population (p=0.009).
Comparison of patients included and excluded from propensity score sub-sample
A comparison of the relevant covariates for participants included in and excluded from our propensity scorePS quintile matched designed subsample is shown in Table E48 , for full and non PAP users separately. We observe that oOn average, excluded full users were heavier, had more severe OSA, were sleepier, had more hypertension, and more likely to use statins. Excluded non-PAP users had higher baseline ICAM-1 levels, lower BMI, less severe AHI, and were more likely to be smokers.
Comparison of change in ICAM-1 and VCAM-1 in the PS Matched and Observational Samples
A comparison of the CAM changes between full and non-users within a propensity score designed sample and an observational study is shown in Table E9 . We observe that the differences between PAP groups were similar in magnitude in the PS matched group compared to the overall observational study results. The result of our model assessment of potential confounding variables is presented for models assessing the relationship between PAP usage and change in ICAM-1. Each potential confounder was added separately to the indicated model in a forward stepwise fashion, retaining the variable that resulted in the largest absolute percent change in the coefficient (β) for full or partial PAP use at each step (shown in bold) and stopping when inclusion of another variable resulted in an absolute change of <15%. Age and gender were modeled as baseline values only. Other continuous covariates (BMI, Epworth Sleepiness Scale) were included in the models as baseline and change from baseline and dichotomous covariates (hypertension, obstructive lung disease, current smoking, statin use and exercise) were included as the combination of baseline and follow-up status (no/no, no/yes, yes/no, yes/yes); *The final adjusted covariate model for change in ICAM-1, which includes ICAM-1 at baseline, hypertension at baseline and follow-up, baseline BMI, and change in BMI. Abbreviations: ICAM-1: Intracellular Adhesion Molecule 1; PAP: Positive Airway Pressure; BMI: Body Mass Index; βFull User: Regression coefficient for full PAP usage; βPartial User: Regression coefficient for partial PAP usage; |% Change|: Absolute value of percent change .0 5% The result of our model assessment of potential confounding variables is presented for models assessing the relationship between PAP usage and change in VCAM-1. Each potential confounder was added separately to the indicated model in a forward stepwise fashion, retaining the variable that resulted in the largest absolute percent change in the coefficient (β) for full or partial PAP use at each step (shown in bold) and stopping when inclusion of another variable resulted in an absolute change in both the PAP coefficients of <15%. Age and gender were modeled as baseline values only. Other continuous covariates (BMI, Epworth Sleepiness Scale) were included in the models as baseline and change from baseline and dichotomous covariates (hypertension, obstructive lung disease, current smoking, statin use and exercise) were included as the combination of baseline and follow-up status (no/no, no/yes, yes/no, yes/yes); *The final adjusted covariate model for change in VCAM-1, which includes VCAM-1 at baseline, hypertension at baseline and follow-up, statin use at baseline and follow-up, baseline BMI, and change in BMI. Pearson correlation coefficients (rho) and p-values are shown for the associations between obesity measures and natural log transformed levels of ICAM-1 and VCAM-1 at baseline. *Baseline ICAM-1 and VCAM-1 levels were natural log transformed in order to achieve normality and allow for parametric analyses. Subgroup specific predicted mean change and standard errors from ANCOVA models testing whether there was a significant association between PAP usage and change in cellular adhesion molecules are presented. *p-value testing whether the predicted least square mean change is significantly different from zero; models adjusted for baseline ICAM-1 or VCAM-1 levels, BMI, change in BMI, hypertension at baseline and follow-up, and statin use at baseline The associations between continuous measures of PAP usage (average hours used and average nights used during the last 28 nights) and cellular adhesion molecule change are presented. *p-value from linear regression model with subject specific change scores as the outcome and PAP usage as a predictor, restricted to the subset of participants who were full or partial users (n=221) 
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